To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Prandin, New Oral Treatment For Type II Diabetes URL: http://www.pslgroup.com/dg/4F00A.htm Doctor's Guide December 23, 1997
BAGSVAERD, DENMARK -- December 23, 1997 -- The United States Food and Drug Administration (FDA) has approved Novo Nordisk A/S's Prandin(TM) (repaglinide), a new agent for treatment of Type II diabetes. Prandin is the first approved product in a new chemical class (meglitinide class) of orally-administered drugs for the treatment of Type II diabetes and was developed to manage meal-related (prandial) glucose loads. It is different from other oral anti-diabetic agents in structure and clearance. Its quick onset and short duration of action concentrates its effect around meal time glucose load, which is important to the treatment of Type II diabetes. If a meal is skipped, so is the Prandin tablet; if a meal is added during the day, a tablet is added for that meal. Prandin stimulates insulin secretion from the beta cells of the pancreas by binding to sites on the beta cell. Prandin is minimally excreted by the kidney, which may be an advantage for patients (often elderly) who often suffer from decreased kidney function. The agent is in-licensed by Novo Nordisk for worldwide development and marketing. The product trade name outside the U.S. will be NovoNorm . --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.